Navigation Links
Cancer Drug May Offer New Hope for Lupus Patients
Date:3/13/2009

Small U.K. study says Rituxan could become 1st new drug for disease in 50 years

FRIDAY, March 13 (HealthDay News) -- The cancer drug Rituxan may offer the first new treatment approved for lupus in 50 years, suggests a small study by U.K. researchers at Imperial College London.

The 22-month study included 20 people with lupus nephritis, a severe kidney disorder caused by the disease lupus. After treatment with Rituxan, 60 percent showed significant signs of improvement, the researchers found. But the drug was not effective in people of African ancestry or in those with very low levels of albumin protein in their blood.

Rituxan targets hyperactive B cells, which contribute to kidney inflammation in people with lupus. If these study results can be repeated in larger trials, Rituxan might be approved to treat lupus, the researchers said.

"This is very welcome news to the 40 percent of lupus patients who are suffering with kidney involvement in their battle with systemic lupus erythematosus, an autoimmune disease, and who until now had very little hope of a breakthrough for lupus nephritis," Virginia T. Ladd, president and executive director of the American Autoimmune Related Diseases Association, said in an association news release.

People with lupus experience a wide range of problems, including muscle pain, extreme fatigue and inflammation of the joints, skin, major organs and central nervous system.

More information

The Lupus Foundation of America has more about lupus.



-- Robert Preidt



SOURCE: American Autoimmune Related Diseases Association, news release, March 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug May Offer New Hope for Lupus Patients
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... 2017 , ... The American Board of Quality Assurance and Utilization Review Physicians ... to Health Care Quality and Management and Patient Safety. , It is with appreciation ... but also to the Health Care Quality and Patient Safety movements. Diplomates and Members ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, ... How will the new EU MDR language change the way manufacturers approach ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Beyond and ... “Beyond and Back” is the creation of published author Bonetta Rose, a wife, mother ... our lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
Breaking Medicine Technology: